Current studies have found that allogenic mesenchymal stem cells (MSCs) transplantation (MSCT) can be used
successfully in mouse and human SLE. However, syngeneic bone marrow (BM)-MSCT was ineffective. Recently, studies
also revealed that BM-MSCs from SLE patients showed senescent behavior. These findings suggested that the senescence
of BM-MSCs from SLE patients may be a contributing factor to disease pathogenesis. So further findings about MSCs
senescence of SLE will contribute to lay the groundwork for the development of new therapeutic approaches to treat SLE.
In this review, we summarize the characteristics of MSCs, molecular mechanisms and signaling involved in MSCs
senescence and the senescent biological behavior of MSCs from SLE and possible mechanisms. Analyzing the
mechanisms of controlling MSCs senescence may provide a therapeutic target for SLE.
Keywords: DNA damage, immunomodulation, Mesenchymal stem cells (MSCs), molecular mechanisms, senescence,
Systemic Lupus Erythematosus (SLE).
Rights & PermissionsPrintExport